COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02375022
Recruitment Status : Unknown
Verified March 2015 by Qiong Zhao, Zhejiang University.
Recruitment status was:  Recruiting
First Posted : March 2, 2015
Last Update Posted : March 24, 2015
Jiangsu Simcere Pharmaceutical Co., Ltd.
Beta Pharma, Inc.
Information provided by (Responsible Party):
Qiong Zhao, Zhejiang University

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : March 2016